Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 47

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 47
---
, and there can be no assurance that
any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate
because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent
limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

32

PART
II: OTHER INFORMATION

Item
1. Legal Proceedings 

We
are not currently a party to any material legal proceedings.

Item
1A. Risk Factors

With
the exception of the changes described and set forth below, there have been no material changes to our risk factors from those disclosed
under “Risk Factors” in Part I, Item 1A of our 2024 Annual Report on Form 10-K. The risks and uncertainties described in
our 2024 Annual Report on Form 10-K, as supplemented by this Form 10-Q, are not the only ones we face. Additional risks and uncertainties
not presently known to us or that we currently deem immaterial may also materially adversely affect our business, financial condition,
or results of operations.

Risks
Related Investing in our Common Stock

Any
market activity involving short selling or other market making activities could result in negative impact to the market price for our
Common Stock.

Short
selling is a method used to capitalize on an expected decline in the market price of a security and could depress the price of our Common
Stock, which could further increase the potential for future short sales. Sales of our Common Stock could encourage short sales by market
participants, which could create negative market momentum. Continued short selling may bring about a temporary, or possibly long term,
decline in the market price of our Common Stock. The Company cannot predict the size of future issuances or sales of Common Stock or
the effect, if any, that future issuances and sales of Common Stock will have on its market price or the activities of short sellers.
Sales involving significant amounts of Common Stock, including issuances made in the ordinary course of the Company’s business,
or the perception that such sales could occur, may materially and adversely affect prevailing market prices of the Common Stock.

Our
Common Stock may be delisted from Nasdaq if we fail to comply with continued listing standards.

Our
Common Stock is currently traded on Nasdaq under the symbol “IMNN.” If we fail to comply with Nasdaq’s continued listing
standards, we may be delisted and our